case, one of the issues that was related to the fact that this is not the safety of dmaa or the unsafety of dmaa which is the ingredient at issue there is not -- there's i would just say there's a controversy or different ideas about that. and you know, to some extent we have to resolve that sometimes in the court system. >> to the extent that the -- that a warning letter triggers the type of litigious activity surrounding the safety of a particular element, does that give it higher priority or does that add to the priority or is that something within the systems that you have to address? >> i think we need to prioritize and you know, your question is a fair one. if we have -- there's a number of warning letters that come out that the agency has a lot of different issues. if it's an issue that we find to be one that has potential harm to consumers, it's a higher risk issue, we should make sure that that gets addressed. >> yes, because it strikes me that i didn't do this kind of work as an attorney but if -- or if you were a gc for a company. if you have a product on the market, the produ